Patent · US Active

MAGE3 polypeptides

US8097257B2 · kind B2 · utility

0Cited by

22References

36Claims

0Family size

Assignee

GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Teresa Cabezon Sil Va · Sint-Genesius-Rode, BE
Joseph Cohen · Brussels, BE
Moncef Slaoui · Rixensart, BE
Carlota Vinals Bassols · Liège, BE

Key dates

Filing date	Dec 17, 2009
Grant date	Jan 17, 2012
Priority date	—
Expiry date	Dec 17, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel MAGE3 polypeptides, including a fragment of MAGE3 fused to an immunological fusion partner, and compositions thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.